|
![]() |
|||
|
||||
OverviewThe internationalization of research and technology is one key component of the globalization of trade and business, with potentially major impacts on patterns of economic development and public policies worldwide. Particularly in the already highly globalized pharmaceutical industry, innovation processes have changed considerably in the last 15 - 20 years. One-dimensional, linear single-actor type processes are being replaced by multi-dimensional, complex, multi-actor schemes. As a consequence, new players are becoming more important, with biotechnology firms playing a key role. This study analyzes these new ways in drug development in pharmaceuticals within the concept of ""national systems of innovations"" as well as from the perspectives of different actors, and collects a lot of empirical evidence for the assumed type of changes, its repercussion on significant input measures and on the differing performance of national pharmaceutical industries. Full Product DetailsAuthor: Andre Jungmittag , Guido Reger , Thomas ReissPublisher: Springer-Verlag Berlin and Heidelberg GmbH & Co. KG Imprint: Springer-Verlag Berlin and Heidelberg GmbH & Co. K Edition: Softcover reprint of the original 1st ed. 2000 Dimensions: Width: 15.50cm , Height: 1.20cm , Length: 23.50cm Weight: 0.740kg ISBN: 9783642086731ISBN 10: 364208673 Pages: 216 Publication Date: 18 December 2010 Audience: Professional and scholarly , Professional & Vocational Format: Paperback Publisher's Status: Active Availability: In Print ![]() This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us. Table of Contents1 Introduction.- 2 The National System of Innovation in the United States and Germany.- 3 Dynamics of the Markets and Market Structure.- 4 Innovation Process and Techno-scientific Dynamics.- 5 Generation, Transfer and Exploitation of New Knowledge.- 6 Internationalization of Research and Development in Pharmaceuticals.- 7 Case Study on New Therapies for Selected Autoimmune Diseases.- 8 Summary and Conclusions.- References.- A Top Twenty Pharmaceutical Companies with Subsidiaries.- B R&D Agreements in the Autoimmune Diseases Area.- C From the Call for Tender for the NIH Program “Autoimmunity Centers of Excellence” Released in May 1998 (NIH 1998).ReviewsAuthor InformationTab Content 6Author Website:Countries AvailableAll regions |